Pharmacology of Anticancer Drugs in the Elderly Population

[1]  A. Cantor,et al.  Can older cancer patients tolerate chemotherapy? , 2003, Cancer.

[2]  M. Aapro,et al.  Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. , 2003, Critical reviews in oncology/hematology.

[3]  F. Gherlinzoni,et al.  Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  H. Burger,et al.  Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines , 2002, British Journal of Cancer.

[5]  G. Lyman,et al.  Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients , 2002, Current opinion in hematology.

[6]  R. Larson,et al.  Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study , 2002, Cancer Chemotherapy and Pharmacology.

[7]  Charles Enke,et al.  Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  David Cella,et al.  Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.

[9]  D. Ribatti,et al.  Docetaxel versus paclitaxel for antiangiogenesis. , 2002, Journal of hematotherapy & stem cell research.

[10]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[11]  B. Reigner,et al.  Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients , 2002, Cancer Chemotherapy and Pharmacology.

[12]  C. Gridelli,et al.  Pharmacokinetics of Navelbine® Oral in Elderly Patients , 2002, Tumori.

[13]  D. Bernardi.  Is it Possible to use Anthracyclines in Patients Older than 70 Years? Pro , 2002, Tumori.

[14]  G. Robustelli della Cuna,et al.  Prospective Phase II Study of Single-Agent Gemcitabine in Untreated Elderly Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer , 2001, American journal of clinical oncology.

[15]  P. Fidias,et al.  A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  S. Culine,et al.  Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. , 2001, European journal of cancer.

[17]  P. Fumoleau,et al.  Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Ferrara,et al.  Acute myeloid leukemia in the elderly: biology and therapeutic strategies. , 2001, Critical reviews in oncology/hematology.

[20]  M. Extermann,et al.  Management of breast cancer in the older woman. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[21]  S. Sleijfer.  Bleomycin-induced pneumonitis. , 2001, Chest.

[22]  A. Sulkes,et al.  Doxorubicin-based chemotherapy in the elderly. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Dan L. Longo,et al.  Cancer Chemotherapy and Biotherapy: Principles and Practice , 2001 .

[24]  K. Maclennan,et al.  Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. , 2001, Blood.

[25]  René Bruno,et al.  Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel , 2001, Investigational New Drugs.

[26]  K. Possinger,et al.  Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study , 2001, Anti-cancer drugs.

[27]  E. Espinosa,et al.  Renal Tolerance to Cisplatin in Patients 70 Years and Older , 2001, American journal of clinical oncology.

[28]  L. Balducci.  The geriatric cancer patient: equal benefit from equal treatment. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[29]  G. Lyman,et al.  Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Hainsworth,et al.  Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. , 2001, Seminars in oncology.

[31]  S. Lichtman,et al.  Pharmacology of antineoplastic agents in older cancer patients. , 2000, Oncology.

[32]  G. Hortobagyi,et al.  Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  J. Schellens,et al.  Pharmacokinetically Guided Administration of Chemotherapeutic Agents , 2000, Clinical pharmacokinetics.

[34]  Sudhakar M. Pai,et al.  Population Pharmacokinetics of Temozolomide in Cancer Patients , 2000, Pharmaceutical Research.

[35]  L. Balducci.  Geriatric oncology: challenges for the new century. , 2000, European journal of cancer.

[36]  A. Ardizzoni,et al.  Full dose (FD) chemotherapy (CT) plus lenograstim and low dose (LD) CT in elderly SCLC patients. A phase II randomized fonicap-GSTPV study , 2000 .

[37]  J. Gibbs,et al.  Plasma Concentration Monitoring of Busulfan , 2000 .

[38]  J. Hainsworth,et al.  Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma , 2000, Cancer.

[39]  G. Rosner,et al.  Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Culine,et al.  Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  S. Johnson.  Clinical Pharmacokinetics of Nucleoside Analogues , 2000, Clinical Pharmacokinetics.

[42]  J. Radford,et al.  A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma. , 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

[43]  F. Cavalli,et al.  Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. Lyman,et al.  What threshold for adjuvant therapy in older breast cancer patients? , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P. Marquet,et al.  Adaptive Control Methods for the Dose Individualisation of Anticancer Agents , 2000, Clinical pharmacokinetics.

[46]  P. Watkins,et al.  The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  H. Pinedo,et al.  Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  F. D. Boudinot,et al.  Age-Related Changes in Protein Binding of Drugs , 2000, Clinical pharmacokinetics.

[49]  R. Yancik,et al.  Aging and cancer in America. Demographic and epidemiologic perspectives. , 2000, Hematology/oncology clinics of North America.

[50]  A. Ezzat,et al.  Optimization of Oral Etoposide Dosage in Elderly Patients with Non‐Hodgkin's Lymphoma Using the Fraction of Dose Absorbed Measured for Each Patient , 2000, Journal of clinical pharmacology.

[51]  M. Aapro,et al.  Assessment of the older cancer patient. , 2000, Hematology/oncology clinics of North America.

[52]  F. D. De Braud,et al.  Ifosfamide in the elderly: clinical considerations for a better drug management. , 2000, Critical reviews in oncology/hematology.

[53]  S. Goodman,et al.  A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer , 2000, Cancer investigation.

[54]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[55]  P. Beale,et al.  Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies , 1999, British Journal of Cancer.

[56]  J. Schellens,et al.  A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel , 1999, Journal of Cancer Research and Clinical Oncology.

[57]  M. Messenger,et al.  Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  D. Platel,et al.  Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. , 1999, Anti-cancer drugs.

[59]  B. Reigner,et al.  Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  M. Gobbi,et al.  Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. , 1999, Blood.

[61]  D. Kerr,et al.  Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil? , 1999, Clinical pharmacokinetics.

[62]  L. Rivory,et al.  Clinical Pharmacokinetics of Docetaxel , 1999, Clinical pharmacokinetics.

[63]  M. Highley,et al.  Role of red blood cells in pharmacokinetics of chemotherapeutic agents. , 1999, Anti-cancer drugs.

[64]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.

[65]  S. Lichtman.  Recent developments in the pharmacology of anticancer drugs in the elderly. , 1998, Current opinion in oncology.

[66]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[67]  H. Gómez,et al.  Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Hainsworth,et al.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Gwilt,et al.  Pharmacokinetics and Pharmacodynamics of Hydroxyurea , 1998, Clinical pharmacokinetics.

[70]  G. Rosner,et al.  Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  B. Reigner,et al.  Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. , 1998, Clinical Cancer Research.

[72]  R. Souhami,et al.  The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. , 1998, British Journal of Cancer.

[73]  L. Grochow,et al.  Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. , 1997, Gynecologic oncology.

[74]  C. Bologna,et al.  Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. , 1997, The Journal of rheumatology.

[75]  R. Vestal.  Aging and pharmacology , 1997, Cancer.

[76]  G. Chabot.  Clinical Pharmacokinetics of Irinotecan , 1997, Clinical pharmacokinetics.

[77]  M. van Glabbeke,et al.  Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  H. Safran,et al.  Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. , 1997, Seminars in oncology.

[79]  G. Paine-Murrieta,et al.  Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. , 1997, European journal of cancer.

[80]  A. Ardizzoni,et al.  Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age , 1997, Aging.

[81]  R. Herbst,et al.  PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. , 1997, In vivo.

[82]  H. Lamb,et al.  Oral Idarubicin , 1997, Drugs & aging.

[83]  M. Gobbi,et al.  Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. , 1997, Blood.

[84]  A. Markham,et al.  Fludarabine , 2012, Drugs.

[85]  L. Wiseman,et al.  Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. , 1997, Drugs & aging.

[86]  G. Rosner,et al.  Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  F. Shepherd,et al.  Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. , 1997, Seminars in oncology.

[88]  S. Swain,et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Y. Fujiwara,et al.  Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics. , 1997, Journal of the National Cancer Institute.

[90]  D. Crivellari,et al.  Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. , 1997, European journal of cancer.

[91]  L. Grochow,et al.  Pharmacology of cancer chemotherapy in the older person. , 1997, Clinics in geriatric medicine.

[92]  B. Coiffier,et al.  Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  D. Girling.  Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial , 1996, The Lancet.

[95]  A. Levis,et al.  The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. , 1996, Leukemia & lymphoma.

[96]  J. Beijnen,et al.  Clinical Pharmacokinetics of Topotecan , 1996, Clinical pharmacokinetics.

[97]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  G. Colantuoni,et al.  Weekly Low Dose Epirubicin in Elderly Cancer Patients , 1996, Tumori.

[99]  G. Hortobagyi,et al.  Doxorubicin-Based Chemotherapy in Elderly Patients With Metastatic Breast Cancer: Tolerance and Outcome , 1996 .

[100]  L. Grochow,et al.  Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  S. Monfardini,et al.  Pharmacokinetics of vinorelbine in patients with liver metastases , 1996, Clinical pharmacology and therapeutics.

[102]  W Hop,et al.  Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  B. Leber,et al.  Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  R. Souhami,et al.  Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals , 1995, Cancer Chemotherapy and Pharmacology.

[105]  S. Rodenhuis,et al.  Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin , 1995, Cancer Chemotherapy and Pharmacology.

[106]  A. Pascarella,et al.  Attenuated‐dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results , 1995, British journal of haematology.

[107]  G. Houin,et al.  Prediction of carboplatin clearance from standard morphological and biological patient characteristics. , 1995, Journal of the National Cancer Institute.

[108]  M. Egorin.  Further refinement of carboplatin dosing. , 1995, Journal of the National Cancer Institute.

[109]  M. Relling,et al.  Clinical Pharmacokinetics of Paclitaxel , 1994, Clinical pharmacokinetics.

[110]  M. Piccart,et al.  Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  M. Bibby,et al.  Pharmacokinetic Drug Interactions with Anticancer Drugs , 1994, Clinical pharmacokinetics.

[112]  J. Robert.  Clinical Pharmacokinetics of Epirubicin , 1994, Clinical pharmacokinetics.

[113]  J. Verweij,et al.  Limited sampling models for topotecan pharmacokinetics. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  J. Robert.  Clinical Pharmacokinetics of Idarubicin , 1993, Clinical pharmacokinetics.

[115]  J. Hainsworth,et al.  Bioavailability of low-dose oral etoposide. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  M. Egorin,et al.  Cancer pharmacology in the elderly. , 1993, Seminars in oncology.

[117]  N. Saijo,et al.  Pharmacokinetic Study of Mitomycin C with Emphasis on the Influence of Aging , 1992, Japanese journal of cancer research : Gann.

[118]  N. Dobbs,et al.  Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. , 1992, British Journal of Cancer.

[119]  F. Demard,et al.  Influence of sex and age on fluorouracil clearance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  R. Dorr,et al.  Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. , 1992, Seminars in oncology.

[121]  M. Ratain,et al.  Modeling interpatient pharmacodynamic variability of etoposide. , 1991, Journal of the National Cancer Institute.

[122]  W. Evans,et al.  Relation of systemic exposure to unbound etoposide and hematologic toxicity , 1991, Clinical pharmacology and therapeutics.

[123]  W. J. Vijgh.  Clinical Pharmacokinetics of Carboplatin , 1991 .

[124]  W. Evans,et al.  Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. , 1990, Cancer research.

[125]  W. Evans,et al.  Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  P. Wilkinson,et al.  The effect of age on the pharmacokinetics of ifosfamide. , 1990, British journal of clinical pharmacology.

[127]  G. Yuen,et al.  Altered pharmacokinetics in the elderly. , 1990, Clinics in geriatric medicine.

[128]  U. Schuler,et al.  Pharmacokinetics and Metabolism of Mitoxantrone A Review , 1990, Clinical pharmacokinetics.

[129]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  P. Crome,et al.  Clinical Pharmacokinetic Considerations in the Elderly , 1989, Clinical pharmacokinetics.

[132]  N. Petrelli,et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[134]  D. Rushing,et al.  Doxorubicin clearance in the obese. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  C. Haanen,et al.  Clinical Pharmacokinetics of Doxorubicin , 1988, Clinical pharmacokinetics.

[136]  R. Demicheli,et al.  Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  A. Hagenbeek,et al.  Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  E. D. de Bruijn,et al.  Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model. , 1987, Cancer treatment reports.

[139]  S M Hubbard,et al.  The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. , 1987, Cancer research.

[140]  M. Slevin,et al.  The Clinical Pharmacology of Etoposide and Teniposide , 1987, Clinical pharmacokinetics.

[141]  P. Gill,et al.  Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  G. Blackledge,et al.  Prediction of ifosfamide/mesna associated encephalopathy. , 1986, European journal of cancer & clinical oncology.

[143]  F. Balis.  Pharmacokinetic Drug Interactions of Commonly Used Anticancer Drugs , 1986, Clinical pharmacokinetics.

[144]  T. Miller,et al.  Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  M. Namer,et al.  CLINICAL AND PHARMACOKINETIC EVIDENCE OF A LIFE-THREATENING INTERACTION BETWEEN METHOTREXATE AND KETOPROFEN , 1986, The Lancet.

[146]  Stephen L. Johnson,et al.  Gastrointestinal absorption as a function of age: Xylose absorption in healthy adults , 1985, Clinical pharmacology and therapeutics.

[147]  A. Buzdar,et al.  Early and delayed clinical cardiotoxicity of doxorubicin , 1985, Cancer.

[148]  R. Gelman,et al.  Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  M. Slevin,et al.  The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. , 1984, British journal of clinical pharmacology.

[151]  B. Kennedy,et al.  Lack of age-dependent cisplatin nephrotoxicity. , 1984, The American journal of medicine.

[152]  J. Robert,et al.  Age dependence of the early-phase pharmacokinetics of doxorubicin. , 1983, Cancer research.

[153]  B. Brenner,et al.  Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. , 1982, The New England journal of medicine.

[154]  H. Genant,et al.  Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. , 1982, The New England journal of medicine.

[155]  R. Comis,et al.  The pulmonary toxicity of antineoplastic agents. , 1982, Seminars in oncology.

[156]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[157]  J. Goldberg,et al.  Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. , 1981, The New England journal of medicine.

[158]  S. Rodenhuis,et al.  Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.

[159]  David C Christiani,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[160]  K. Weismann,et al.  Renal function and the rate of disappearance of methotrexate from serum , 1975, European Journal of Clinical Pharmacology.

[161]  R. Benjamin.  Pharmacokinetics of adriamycin (NSC-123127) in patients with sarcomas. , 1974, Cancer chemotherapy reports.

[162]  E. De Clercq,et al.  Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine , 2005, Journal of Cancer Research and Clinical Oncology.

[163]  J. Verweij,et al.  Relationship between clinical parameters and pharmacokinetics of mitomycin C , 2004, Journal of Cancer Research and Clinical Oncology.

[164]  P. Wilkinson,et al.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution , 2004, Cancer Chemotherapy and Pharmacology.

[165]  P. Hartvig,et al.  Inter- and intraindividual differences in oral chlorambucil pharmacokinetics , 2004, European Journal of Clinical Pharmacology.

[166]  S. Urien,et al.  Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood , 2004, Cancer Chemotherapy and Pharmacology.

[167]  L. Grochow,et al.  Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data , 2004, Cancer Chemotherapy and Pharmacology.

[168]  S. Joel,et al.  Etoposide dosage and pharmacodynamics , 2004, Cancer Chemotherapy and Pharmacology.

[169]  K. Itoh,et al.  Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11 , 2004, Investigational New Drugs.

[170]  K. Eguchi,et al.  The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function , 2004, Cancer Chemotherapy and Pharmacology.

[171]  F. Juma.  Effect of liver failure on the pharmacokinetics of cyclophosphamide , 2004, European Journal of Clinical Pharmacology.

[172]  Z. Desai,et al.  Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? , 2004, Cancer Chemotherapy and Pharmacology.

[173]  R. Labianca,et al.  Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[175]  S. Lichtman,et al.  Pharmacokinetic Considerations of Oral Chemotherapy in Elderly Patients with Cancer , 2002, Drugs & aging.

[176]  T. Kumakawa,et al.  Prognosis of Elderly Patients With Acute Myelogenous Leukemia: Analysis of 126 AML Cases , 2002, International journal of hematology.

[177]  S. Culine,et al.  Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer , 2001, Cancer Chemotherapy and Pharmacology.

[178]  K. Blesch,et al.  Clinical Pharmacokinetics of Capecitabine , 2001, Clinical pharmacokinetics.

[179]  A. Gadducci,et al.  Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. , 2001, Critical reviews in oncology/hematology.

[180]  G. Marotta,et al.  Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. , 2000, Haematologica.

[181]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  N. Saijo,et al.  Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age , 2000, Cancer Chemotherapy and Pharmacology.

[183]  J. Misset,et al.  Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function , 2000, Cancer Chemotherapy and Pharmacology.

[184]  M. Rosenthal,et al.  High-dose methotrexate for primary CNS lymphoma in the elderly. , 2000, Neuro-oncology.

[185]  S. Culine,et al.  Population pharmacokinetics of topotecan: intraindividual variability in total drug , 2000, Cancer Chemotherapy and Pharmacology.

[186]  F. Lévi,et al.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects. , 2000, Clinical pharmacokinetics.

[187]  B. Reigner,et al.  Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients , 1999, Cancer Chemotherapy and Pharmacology.

[188]  B. Reigner,et al.  Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients , 1999, Cancer Chemotherapy and Pharmacology.

[189]  P. Queirolo,et al.  Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells. , 1999, Anticancer research.

[190]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  M. Zucchetti,et al.  Pharmacokinetics of anticancer agents in patients with impaired liver function. , 1998, European journal of cancer.

[192]  R. Mick,et al.  Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[193]  M Van Glabbeke,et al.  CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  M. Fukuoka,et al.  Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer , 1997, Cancer Chemotherapy and Pharmacology.

[195]  A. Levis,et al.  Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. , 1996, Haematologica.

[196]  N. Petrelli,et al.  Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial , 1995, Cancer.

[197]  R. Dorr,et al.  Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. , 1995, Cancer treatment reviews.

[198]  Y. Esumi,et al.  Placental transfer, lacteal transfer and plasma protein binding of gemcitabine. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[199]  D. Lowenthal,et al.  Geriatric pharmacology: basic and clinical considerations. , 1992, Annual review of pharmacology and toxicology.

[200]  R. Herrmann,et al.  Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. , 1991, Oncology.

[201]  R. Verbeeck,et al.  Plasma Protein Binding of Drugs in the Elderly , 1987, Clinical pharmacokinetics.

[202]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[203]  G. Bonadonna,et al.  Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.

[204]  Robert J. Anderson,et al.  Clinical use of drugs in renal failure , 1976 .

[205]  G. Pinkus,et al.  Hodgkin's disease in the elderly. , 1974, Oncology.